Paper Details

  1. Home
  2. Paper Details

Chemotherapy for advanced malignant melanoma.

Author: BuzaidA C, MurrenJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Treatment for metastatic melanoma remains challenging. The combination of cisplatin, dacarbazine, carmustine, and tamoxifen shows promise with a response rate of nearly 50%, but further research is needed to confirm its efficacy and evaluate the role of tamoxifen. Biological response modifiers, while limited as single agents, show some potential when combined with cytotoxic agents. Future research should focus on developing more effective treatments and exploring the use of aggressive adjuvant and neoadjuvant chemotherapy for high-risk patients.
Paper Details　
Original Abstract of the Article :
Systemic chemotherapy for the treatment of metastatic melanoma remains disappointing. Nor new single agent has demonstrated promising results. The combination of cisplatin, decarbazine, carmustine, and tamoxifen appears to be one of the most active regimens with an overall response rate approaching ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02591647

データ提供：米国国立医学図書館（NLM）

Melanoma: A Stubborn Camel in the Desert of Cancer

This study explores the challenges of treating advanced malignant melanoma, a type of skin cancer that can be very aggressive. Imagine a stubborn camel that refuses to be tamed, continuing its journey through the desert of cancer, even after treatment. The researchers sought to find more effective treatments for this disease, like finding ways to redirect the camel's path or weaken its resolve.

Finding a New Oasis

The study found that a combination of chemotherapy drugs, including cisplatin, decarbazine, carmustine, and tamoxifen, showed promising results, achieving a response rate of nearly 50%. This is like finding a hidden oasis in the desert, offering respite and hope for survival.

The Search Continues

The researchers highlight the need for further research to develop more effective treatments, emphasizing the importance of aggressive adjuvant and neoadjuvant chemotherapy for high-risk patients. This is like continuing to search for new oases in the desert, seeking ways to improve the chances of survival against this stubborn foe.

Dr. Camel's Conclusion

The study reminds us that the battle against melanoma is a challenging journey through the desert of cancer. The researchers’ findings offer hope for better treatments, but the search for a cure continues, driven by the need to provide effective solutions for those facing this formidable foe.

Date :
  1. Date Completed 1992-06-26
  2. Date Revised 2019-10-28
Further Info :

Pubmed ID

1591369

DOI: Digital Object Identifier

10.1007/BF02591647

Related Literature

Article Analysis
・Effective treatment of melanoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.